Effect of Danhong injection on prognosis and inflammatory factor expression in patients with acute coronary syndrome during the perioperative period of percutaneous coronary intervention: A systematic review and meta-analysis
ObjectivesIn China, Danhong injection (DHI) is recommended by expert consensus and is widely used in the perioperative management of patients with acute coronary syndrome (ACS). This study investigates the effect of perioperative DHI administration and the timing of DHI administration on patients wi...
| Main Authors: | , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2022-11-01
|
| Series: | Frontiers in Cardiovascular Medicine |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fcvm.2022.1029387/full |
| _version_ | 1797984019938279424 |
|---|---|
| author | Yuxuan Li Dong Li Wujiao Wang Xingxing Li Peng Li Yuanyuan Zhang Qian Lin Yan Li |
| author_facet | Yuxuan Li Dong Li Wujiao Wang Xingxing Li Peng Li Yuanyuan Zhang Qian Lin Yan Li |
| author_sort | Yuxuan Li |
| collection | DOAJ |
| description | ObjectivesIn China, Danhong injection (DHI) is recommended by expert consensus and is widely used in the perioperative management of patients with acute coronary syndrome (ACS). This study investigates the effect of perioperative DHI administration and the timing of DHI administration on patients with ACS undergoing percutaneous coronary intervention (PCI) by analyzing the prognosis and anti-inflammatory effects. This article summarizes the most up-to-date clinical evidence on DHI, and in this study, we assesses treatment efficacy of DHI in patients with ACS.MethodsA total of seven databases (PubMed, Embase, Cochrane Library, SINOMED, CNKI, Wanfang, and VIP) were searched from the time of their inception to 1 July 2022. Clinical randomized controlled trials (RCTs) of DHI combined with PCI for the treatment of ACS were included. RCT quality was assessed using the Cochrane Handbook risk-of-bias tool, and STATA 17.0 was used for meta-analysis.ResultsIn total, 33 studies including 3,458 patients with ACS undergoing PCI were included in the meta-analysis. Compared with conventional therapy alone, the combination of DHI and conventional therapy significantly decreased the incidence of major adverse cardiovascular events (MACEs; P<0.001) and improved the reperfusion rate (P < 0.001). Serum high-sensitivity C-reactive protein (hs-CRP) and interleukin (IL)-6 levels were substantially reduced in the test group (P<0.001). In addition, the plasma levels of myocardial injury markers and cardiac troponin T (cTnT) declined significantly (P < 0.01). Compared with the control group, DHI improved the left ventricular ejection fraction (LVEF; P < 0.001) and reduced B-type natriuretic peptide (BNP; P < 0.001) levels. Subgroups were established based on different timings of DHI administration: preoperative, intraoperative, and postoperative groups. The results showed that the incidence of MACEs and the reperfusion rate did not differ between the groups. Among the subgroups, the postoperative group exhibited significantly lower levels of BNP, hs-CRP, and IL-6 serum and a significantly higher level of LVEF (P < 0.05).ConclusionThe combination of DHI and conventional therapy results in a better therapeutic effect than that observed with conventional therapy alone in patients with ACS. To improve treatment efficacy, postoperative initiation of DHI is recommended as a standard treatment. Further research is needed to confirm these results.Systematic review registrationIdentifier: CRD42022344830. |
| first_indexed | 2024-04-11T06:56:11Z |
| format | Article |
| id | doaj.art-ea1d2980bf47411aba90b3faf3d1c605 |
| institution | Directory Open Access Journal |
| issn | 2297-055X |
| language | English |
| last_indexed | 2024-04-11T06:56:11Z |
| publishDate | 2022-11-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Cardiovascular Medicine |
| spelling | doaj.art-ea1d2980bf47411aba90b3faf3d1c6052022-12-22T04:39:02ZengFrontiers Media S.A.Frontiers in Cardiovascular Medicine2297-055X2022-11-01910.3389/fcvm.2022.10293871029387Effect of Danhong injection on prognosis and inflammatory factor expression in patients with acute coronary syndrome during the perioperative period of percutaneous coronary intervention: A systematic review and meta-analysisYuxuan Li0Dong Li1Wujiao Wang2Xingxing Li3Peng Li4Yuanyuan Zhang5Qian Lin6Yan Li7Second Clinical School of Medicine, Beijing University of Chinese Medicine, Beijing, ChinaDepartment of Cardiology, Dongfang Hospital, Beijing University of Chinese Medicine, Beijing, ChinaSecond Clinical School of Medicine, Beijing University of Chinese Medicine, Beijing, ChinaSecond Clinical School of Medicine, Beijing University of Chinese Medicine, Beijing, ChinaSecond Clinical School of Medicine, Beijing University of Chinese Medicine, Beijing, ChinaSecond Clinical School of Medicine, Beijing University of Chinese Medicine, Beijing, ChinaDepartment of Cardiology, Dongzhimen Hospital, Beijing University of Chinese Medicine, Beijing, ChinaDepartment of Cardiology, Dongfang Hospital, Beijing University of Chinese Medicine, Beijing, ChinaObjectivesIn China, Danhong injection (DHI) is recommended by expert consensus and is widely used in the perioperative management of patients with acute coronary syndrome (ACS). This study investigates the effect of perioperative DHI administration and the timing of DHI administration on patients with ACS undergoing percutaneous coronary intervention (PCI) by analyzing the prognosis and anti-inflammatory effects. This article summarizes the most up-to-date clinical evidence on DHI, and in this study, we assesses treatment efficacy of DHI in patients with ACS.MethodsA total of seven databases (PubMed, Embase, Cochrane Library, SINOMED, CNKI, Wanfang, and VIP) were searched from the time of their inception to 1 July 2022. Clinical randomized controlled trials (RCTs) of DHI combined with PCI for the treatment of ACS were included. RCT quality was assessed using the Cochrane Handbook risk-of-bias tool, and STATA 17.0 was used for meta-analysis.ResultsIn total, 33 studies including 3,458 patients with ACS undergoing PCI were included in the meta-analysis. Compared with conventional therapy alone, the combination of DHI and conventional therapy significantly decreased the incidence of major adverse cardiovascular events (MACEs; P<0.001) and improved the reperfusion rate (P < 0.001). Serum high-sensitivity C-reactive protein (hs-CRP) and interleukin (IL)-6 levels were substantially reduced in the test group (P<0.001). In addition, the plasma levels of myocardial injury markers and cardiac troponin T (cTnT) declined significantly (P < 0.01). Compared with the control group, DHI improved the left ventricular ejection fraction (LVEF; P < 0.001) and reduced B-type natriuretic peptide (BNP; P < 0.001) levels. Subgroups were established based on different timings of DHI administration: preoperative, intraoperative, and postoperative groups. The results showed that the incidence of MACEs and the reperfusion rate did not differ between the groups. Among the subgroups, the postoperative group exhibited significantly lower levels of BNP, hs-CRP, and IL-6 serum and a significantly higher level of LVEF (P < 0.05).ConclusionThe combination of DHI and conventional therapy results in a better therapeutic effect than that observed with conventional therapy alone in patients with ACS. To improve treatment efficacy, postoperative initiation of DHI is recommended as a standard treatment. Further research is needed to confirm these results.Systematic review registrationIdentifier: CRD42022344830.https://www.frontiersin.org/articles/10.3389/fcvm.2022.1029387/fullDanhong injection (DHI)perioperative periodacute coronary syndrome (ACS)prognosisinflammatory factor expressionpercutaneous coronary intervention (PCI) |
| spellingShingle | Yuxuan Li Dong Li Wujiao Wang Xingxing Li Peng Li Yuanyuan Zhang Qian Lin Yan Li Effect of Danhong injection on prognosis and inflammatory factor expression in patients with acute coronary syndrome during the perioperative period of percutaneous coronary intervention: A systematic review and meta-analysis Frontiers in Cardiovascular Medicine Danhong injection (DHI) perioperative period acute coronary syndrome (ACS) prognosis inflammatory factor expression percutaneous coronary intervention (PCI) |
| title | Effect of Danhong injection on prognosis and inflammatory factor expression in patients with acute coronary syndrome during the perioperative period of percutaneous coronary intervention: A systematic review and meta-analysis |
| title_full | Effect of Danhong injection on prognosis and inflammatory factor expression in patients with acute coronary syndrome during the perioperative period of percutaneous coronary intervention: A systematic review and meta-analysis |
| title_fullStr | Effect of Danhong injection on prognosis and inflammatory factor expression in patients with acute coronary syndrome during the perioperative period of percutaneous coronary intervention: A systematic review and meta-analysis |
| title_full_unstemmed | Effect of Danhong injection on prognosis and inflammatory factor expression in patients with acute coronary syndrome during the perioperative period of percutaneous coronary intervention: A systematic review and meta-analysis |
| title_short | Effect of Danhong injection on prognosis and inflammatory factor expression in patients with acute coronary syndrome during the perioperative period of percutaneous coronary intervention: A systematic review and meta-analysis |
| title_sort | effect of danhong injection on prognosis and inflammatory factor expression in patients with acute coronary syndrome during the perioperative period of percutaneous coronary intervention a systematic review and meta analysis |
| topic | Danhong injection (DHI) perioperative period acute coronary syndrome (ACS) prognosis inflammatory factor expression percutaneous coronary intervention (PCI) |
| url | https://www.frontiersin.org/articles/10.3389/fcvm.2022.1029387/full |
| work_keys_str_mv | AT yuxuanli effectofdanhonginjectiononprognosisandinflammatoryfactorexpressioninpatientswithacutecoronarysyndromeduringtheperioperativeperiodofpercutaneouscoronaryinterventionasystematicreviewandmetaanalysis AT dongli effectofdanhonginjectiononprognosisandinflammatoryfactorexpressioninpatientswithacutecoronarysyndromeduringtheperioperativeperiodofpercutaneouscoronaryinterventionasystematicreviewandmetaanalysis AT wujiaowang effectofdanhonginjectiononprognosisandinflammatoryfactorexpressioninpatientswithacutecoronarysyndromeduringtheperioperativeperiodofpercutaneouscoronaryinterventionasystematicreviewandmetaanalysis AT xingxingli effectofdanhonginjectiononprognosisandinflammatoryfactorexpressioninpatientswithacutecoronarysyndromeduringtheperioperativeperiodofpercutaneouscoronaryinterventionasystematicreviewandmetaanalysis AT pengli effectofdanhonginjectiononprognosisandinflammatoryfactorexpressioninpatientswithacutecoronarysyndromeduringtheperioperativeperiodofpercutaneouscoronaryinterventionasystematicreviewandmetaanalysis AT yuanyuanzhang effectofdanhonginjectiononprognosisandinflammatoryfactorexpressioninpatientswithacutecoronarysyndromeduringtheperioperativeperiodofpercutaneouscoronaryinterventionasystematicreviewandmetaanalysis AT qianlin effectofdanhonginjectiononprognosisandinflammatoryfactorexpressioninpatientswithacutecoronarysyndromeduringtheperioperativeperiodofpercutaneouscoronaryinterventionasystematicreviewandmetaanalysis AT yanli effectofdanhonginjectiononprognosisandinflammatoryfactorexpressioninpatientswithacutecoronarysyndromeduringtheperioperativeperiodofpercutaneouscoronaryinterventionasystematicreviewandmetaanalysis |